Jyoti S. Mayadev, MD, Discusses Rationale for Assessing Durvalumab/CRT Vs Placebo/CRT in High-Risk Locally Advanced Cervical Cancer

Video

The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.

At the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Jyoti S. Mayadev, MD, a radiation oncologist and professor of radiation medicine and applied sciences at the University of California, San Diego School of Medicine, spoke with CancerNetwork® about the rationale of the phase 3 CALLA trial (NCT03830866) assessing durvalumab (Infinzi) in combination with chemoradiotherapy (CRT) compared with placebo and CRT in patients with high-risk locally advanced cervical cancer.

Mayadev also explained how the trial could potentially fulfil unmet needs in a population of patients with recurrence rates that are in need of improvement.

Transcript:

Locally advanced cervical cancer continues to represent an unmet medical need, especially in patients who have node-positive and periodic node–positive disease for which recurrence rates have been historically more than 50%. As a community of radiation oncologists who specialize in cervical cancer we really want to improve upon outcomes for these patients with cervical cancer. At the same time, we know that the majority of cervical cancer is caused by human papillomavirus; we know that it's immunogenic. We've done a series of phase 1 trials through the National Cancer Institute [NCI] that have shown us that combining immunotherapy with chemoradiation, whether it's concurrently or sequentially, is safe and tolerable and has shown really nice signals of efficacy. With AstraZeneca as our study sponsor, we were able to move immunotherapy and chemoradiation in the up-front definitive setting for patients with high-risk, stage III/IV node-positive locally advanced cervical cancer.

The goal of the CALLA trial was to improve outcomes for patients with this disease. It was a randomized, placebo-controlled double-blinded phase 3 trial looking at durvalumab concurrently and sequentially with chemoradiotherapy vs placebo/chemoradiation.

Reference

Mayadev JS, Rong, Y, Toita T, et al. Durvalumab in combination with chemoradiotherapy (CRT) in locally advanced cervical cancer (LACC): radiotherapy (RT) delivery and subgroup analyses from CALLA. Presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting; October 23-26, 2022; San Antonio, TX; LBA 03. Accessed October 27, 2022.

Related Videos
Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.
FDA-approved immunotherapy options such as atezolizumab and durvalumab have produced substantial benefits in certain groups of patients with extensive-stage small cell lung cancer, says Gregory Peter Kalemkerian, MD.
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Treatment with sotorasib or adagrasib appears to be more tolerable among patients with KRAS G12C-mutated non–small cell lung cancer compared with docetaxel, according to Sandip Patel, MD.
Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content